Blog Archive

Sunday, January 31, 2016

A NEW HEMOPHILIA A TREATMENT FROM BAXALTA

It’s a new year, and a new opportunity to check out one of the latest hemophilia treatments to come on the market – ADYNOVATE [Antihemophilic Factor (Recombinant), PEGylated] from Baxalta. Later this year PEN will publish a complete listing of all current products. For now, please read about the newest hemophilia A treatment!



ADYNOVATE [Antihemophilic Factor (Recombinant), PEGylated] delivers proven prophylaxis with a simple, twice-weekly dosing schedule. ADYNOVATE allows you to infuse on the same 2 days every week.1

ADYNOVATE is intended for people 12 years and older with hemophilia A for on-demand treatment and control of bleeding episodes and routine prophylaxis to reduce the frequency of bleeding episodes. ADYNOVATE is not used to treat von Willebrand disease.1

You should not use ADYNOVATE if you:
  • Are allergic to mice or hamster protein
  • Are allergic to any ingredients in ADYNOVATE or ADVATE [Antihemophilic Factor (Recombinant)]
Tell your healthcare provider if you are pregnant or breastfeeding because ADYNOVATE may not be right for you.

You may be eligible to receive 8 free sample doses of ADYNOVATE with the Freedom of Choice trial program. The program also provides resources to help you with your hemophilia A treatment. Complete the registration form here.
Want to learn more?
  • Get access to programs for people living with hemophilia regardless of treatment.
  • Download resources designed to help you reach your personal goals including a Goals Worksheet, Bleeds Assessment Sheet, ABR Calculator, and Infusion Log.
  • Visit our FAQs page for helpful questions and answers when considering your hemophilia A treatment.
ADYNOVATE [Antihemophilic Factor (Recombinant), PEGylated] Important Information

Indication

ADYNOVATE is used on-demand to control bleeding in patients 12 years of age and older with hemophilia A. ADYNOVATE can reduce the number of bleeding episodes when used regularly (prophylaxis).

ADYNOVATE is not used to treat von Willebrand disease.

DETAILED IMPORTANT RISK INFORMATION
You should not use ADYNOVATE if you:
  • Are allergic to mice or hamster protein
  • Are allergic to any ingredients in ADYNOVATE or ADVATE [Antihemophilic Factor (Recombinant)]
     
Tell your healthcare provider if you are pregnant or breastfeeding because ADYNOVATE may not be right for you.

You should tell your healthcare provider if you:
  • Have or have had any medical problems.
  • Take any medicines, including prescription and non-prescription medicines, such as over-the-counter medicines, supplements or herbal remedies.
  • Have any allergies, including allergies to mice or hamsters.
  • Have been told that you have inhibitors to factor VIII (because ADYNOVATE may not work for you).
Your body may form inhibitors to Factor VIII. An inhibitor is part of the body's normal defense system. If you form inhibitors, it may stop ADYNOVATE from working properly. Consult with your healthcare provider to make sure you are carefully monitored with blood tests for the development of inhibitors to Factor VIII.

You can have an allergic reaction to ADYNOVATE.
Call your healthcare provider right away and stop treatment if you get a rash or hives, itching, tightness of the throat, chest pain or tightness, difficulty breathing, lightheadedness, dizziness, nausea or fainting.

The common side effects of ADYNOVATE are headache and nausea. Tell your healthcare provider about any side effects that bother you or do not go away.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

Please see the accompanying Patient Labeling. To see the Full Prescribing Information, go to www.ADYNOVATE.com.
Reference:
1. ADYNOVATE Prescribing Information. Westlake Village, CA: Baxalta US Inc.

Baxalta and Adynovate are trademarks of Baxalta Incorporated.
USBS/MG159/15-0292

The content of this blog was provided by Baxalta and its publication is sponsored by Baxalta.
 
Bayer